ALLOSTERIC INHIBITORS TARGET KRAS IN A MUTANT-SPECIFIC MANNER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2014年 / 4卷 / 01期
关键词：
D O I：
10.1158/2159-8290.CD-RW2013-260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [1] Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA
    Pecot, C.
    Van Swearingen, A.
    Papke, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S456 - S456
  • [2] Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance
    Steinbrunn, Torsten
    Shirasaki, Ryosuke
    Dashevsky, Olga
    Tang, Huihui
    Yamano, Shizuka
    Mizuno, Rin
    Sugihara, Takeru
    Teoh, Phaik Ju
    Leypoldt, Lisa B.
    Kaji, Mariko
    Sorrell, Jeffrey
    Glassner, Brian J.
    Simoes, Ricardo De Matos
    Christensen, James
    Mitsiades, Constantine S.
    BLOOD, 2023, 142
  • [3] KRAS mutant-specific interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic function
    Sundararaj, Kamala
    Burge, Rachel
    Saberikashani, Samaneh
    Bialousow, Lucas
    Linke, Amanda
    Smith, Merissa
    Ostrowski, Michael C.
    O'Bryan, John P.
    Hobbs, G. Aaron
    CANCER RESEARCH, 2024, 84 (02)
  • [4] Computational modeling provides new insights into KRAS mutant-specific responses to targeted therapy
    Stites, Edward C.
    CANCER RESEARCH, 2015, 75 (22)
  • [5] Development of mutant-specific small molecule inhibitors of K-Ras.
    Ostrem, Jonathan M.
    Peters, Ulf
    Ren, Pingda
    Lu, Yi
    Wells, James A.
    Shokat, Kevan M.
    CANCER RESEARCH, 2013, 73 (08)
  • [6] Mutant-specific gene programs in the zebrafish
    Weber, GJ
    Choe, SE
    Dooley, KA
    Paffett-Lugassy, NN
    Zhou, Y
    Zon, LI
    BLOOD, 2005, 106 (02) : 521 - 530
  • [7] KRAS mutant-specific protein interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic regulation.
    Hobbs, Guy Aaron
    Burge, Rachel
    Linke, Amanda
    Sundararaj, Kamala
    O'Bryan, John P.
    CANCER RESEARCH, 2022, 82 (22) : 96 - 97
  • [8] Developing mutant-specific inhibitors of HER2 incorporating bridging water molecules
    Guo, Jiaye
    Collins, Stephen
    Miller, Todd
    Rizzo, Robert
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [9] PHARMACOLOGICAL RESCUE OF MUTANT CFTR: EXPLORING MUTANT-SPECIFIC THERAPIES
    Cholon, D. M.
    Quinney, N. L.
    Chaudhry, I. G.
    Guimbellot, J. S.
    Chua, M.
    Boyles, S. E.
    Houck, S. A.
    Dokholyan, N., V
    Randell, S. H.
    Gentzsch, M.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 194 - 195
  • [10] Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma
    Goetz, Andrew
    Shanahan, Frances
    Brooks, Logan
    Lin, Eva
    Mroue, Rana
    Dela Cruz, Darlene
    Hunsaker, Thomas
    Czech, Bartosz
    Dixit, Purushottam
    Segal, Udi
    Martin, Scott
    Foster, Scott A.
    Gerosa, Luca
    CANCERS, 2024, 16 (16)
12345